Our data do support previous retrospective studies that have reported improved TIR, alongside reduced TAR (both >180 mg/dL [>10.0 mmol/L] and >250 mg/dL [>13.9 mmol/L]) and lower glycaemic variability with increased daily insulin bolus frequencies for adult connected insulin pen users with T1D18 and for people with diabetes on basal‐bolus insulin therapy, but diabetes type not known.19 This evidence concerns the gene INS and diabetes mellitus.